Haemonetics Corporation

Valuation Analysis

About the Company

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire,

Haemonetics Corporation Stock at a Glance

Haemonetics Corporation (HAE) is currently trading at $78.20 with a market capitalization of $3.6B. The trailing P/E ratio stands at 38.15x, with a forward P/E of 13.58x. The 52-week range spans from $47.32 to $87.32; the current price is 10.4% below the yearly high. Year-over-year revenue growth stands at +4.8%. The net profit margin stands at 7.29%.

💰 Dividend

Haemonetics Corporation currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

10 analysts rate Haemonetics Corporation (HAE) on consensus: Buy. The average price target is $83.10, implying +6.27% from the current price. Analyst price targets range from $62.00 to $104.00.

Haemonetics Corporation: The Investment Case in Detail

Haemonetics Corporation (HAE) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bear Case

Revenue growth has slowed to just 4.8%, which is below nominal GDP — the business is no longer outgrowing the broader economy. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valuation in Context

The PEG ratio at 1.25 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric.

What to Watch Next

• The forward P/E of 13.58x is meaningfully below the trailing 38.15x — analysts expect earnings to step up; the next earnings release is the test.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

The price is in a transition zone relative to the moving averages — no clear signal.

Risk Profile

The data points to relatively defensive market behavior, elevated short interest (8.82%), higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy Haemonetics Corporation?

Compare top-rated brokers — low fees, trusted providers, fully regulated.